Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed

Market Focus

06/12

On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.

On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.

This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.

Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1169123803"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169123803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169123803?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169123803","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed","media":"Market Focus","content":"<p><p>On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.</p><p>On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.</p><p>This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.</p><p>Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 01:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.</p><p>On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.</p><p>This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.</p><p>Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1169123803","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169123803","pubTimestamp":1781200084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.On the news front, the company disclosed preliminary clinical results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"动静快讯|Arrowhead Pharmaceuticals常规交易涨5.89%阿尔茨海默病siRNA药物初步临床数据披露","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}